Sangamo Therapeutics (SGMO) Enterprise Value (2016 - 2025)
Sangamo Therapeutics (SGMO) has 16 years of Enterprise Value data on record, last reported at -$30.5 million in Q3 2025.
- For Q3 2025, Enterprise Value rose 22.12% year-over-year to -$30.5 million; the TTM value through Sep 2025 reached -$30.5 million, up 22.12%, while the annual FY2024 figure was -$41.9 million, 7.27% up from the prior year.
- Enterprise Value reached -$30.5 million in Q3 2025 per SGMO's latest filing, up from -$38.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$25.2 million in Q1 2025 and bottomed at -$588.0 million in Q1 2021.
- Average Enterprise Value over 5 years is -$190.6 million, with a median of -$100.4 million recorded in 2022.
- Peak YoY movement for Enterprise Value: crashed 64.25% in 2021, then soared 80.58% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$376.5 million in 2021, then soared by 73.33% to -$100.4 million in 2022, then surged by 55.0% to -$45.2 million in 2023, then rose by 7.27% to -$41.9 million in 2024, then increased by 27.17% to -$30.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$30.5 million in Q3 2025, -$38.3 million in Q2 2025, and -$25.2 million in Q1 2025.